| 今开：0.0 | 昨收：9.09 |
| 最高：0.0 | 最低：0.0 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：1.1987908E9 |
airlight2015-05-31 08:44
$Cell Therapeutics(CTIC)$ ：News From YAHOO FINANCIAL:
As previously reported, the trial met its primary endpoint of spleen volume reduction (35 percent or greater from baseline to Week 24 by MRI/CT scan) in the intent-to-treat population (ITT). These results included pati...查看全文
airlight2015-05-31 08:43
$Cell Therapeutics(CTIC)$ ：
:News From YAHOO FINANCIAL:
PERSIST-1 Findings Presented at ASCO
PERSIST-1 is a randomized (2:1), controlled Phase 3 registration-directed trial comparing the efficacy and safety of pacritinib to best available therapy (BAT) – which incl...查看全文
airlight2015-05-31 08:42
$Cell Therapeutics(CTIC)$ ：:News From YAHOO FINANCIAL
Myelofibrosis is associated with significantly reduced quality of life and shortened survival. Spleen enlargement (splenomegaly) is a common and debilitating symptom of myelofibrosis. As the disease progresses, the bod...查看全文
airlight2015-05-31 08:41
$Cell Therapeutics(CTIC)$ ：:News From YAHOO FINANCIAL
"Myelofibrosis is a difficult-to-treat, rare chronic blood cancer in need of new options that can help overcome the many unique and burdensome symptoms that patients with this disease face on a regular basis, such ...查看全文
airlight2015-05-31 08:40
$Cell Therapeutics(CTIC)$ ：:News From YAHOO FINANCIAL
CHICAGO, May 30, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International's Bioscience business (BAX) today announced data from PERSIST-1 – a randomized Phase 3 regi...查看全文
airlight2015-05-31 08:36
$Cell Therapeutics(CTIC)$ ：:News From YAHOO FINANCIALStudy demonstrates improvement in key disease measurements and disease-related symptoms with pacritinib treatment compared to best available therapy, regardless of platelet levels at the time of enrollment
Treatment res...查看全文
airlight2015-05-31 08:30
$Cell Therapeutics(CTIC)$ :News From YAHOO FINANCIAL
Phase 3 Pacritinib( 藥名 )
Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
3期研究显示pacritinib在ASCO 2015晚打破会话骨髓纤维化患者的重要临...查看全文
xiangxing2015-04-23 14:09
$Cell Therapeutics(CTIC)$ CTI今天宣布：计划在2015年5月6日星期三报告其2015第一季度财务业绩。公告宣布后，管理团队的成员将举办一个网络直播电话会议。查看全文
格隆汇5月10日丨CTI生物制药(CTIC.US)涨84.85%，报8.91美元，总市值11亿美元。瑞典Orphan Biovitrum AB将以17亿美元，每股9.10美元的价格收购CTI的所有流通股。 责任编辑：郭明煜 网页链接
$CTI BioPharma(CTIC)$ 15-12G Securities registration termination [Section 12(g)] Accession Number: 0001193125-23-182785 Act: 34 Size: 10 KB 网页链接
$CTI BioPharma(CTIC)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001893 Act: 33 Size: 1 KB 网页链接
$CTI BioPharma(CTIC)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001895 Act: 33 Size: 1 KB 网页链接
$CTI BioPharma(CTIC)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001909 Act: 33 Size: 1 KB 网页链接
$CTI BioPharma(CTIC)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001878 Act: 33 Size: 1 KB 网页链接
$CTI BioPharma(CTIC)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001881 Act: 33 Size: 1 KB 网页链接
$CTI BioPharma(CTIC)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001933 Act: 33 Size: 1 KB 网页链接
$CTI BioPharma(CTIC)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001885 Act: 33 Size: 1 KB 网页链接
$CTI BioPharma(CTIC)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001900 Act: 33 Size: 1 KB 网页链接
$CTI BioPharma(CTIC)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001914 Act: 33 Size: 1 KB 网页链接